Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment
(2023)
Journal Article
Fayyaz, H. A., EL-Massik, M. A., Bahey-El-Din, M., Abdel-Bary, A., Abdallah, O. Y., & Eltaher, H. M. (2024). Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment. International Journal of Pharmaceutics, 649, Article 123663. https://doi.org/10.1016/j.ijpharm.2023.123663
Invasive pulmonary aspergillosis (IPA) is the most devastating Aspergillus-related lung disease. Voriconazole (VRZ) is the first-line treatment against IPA. Despite availability in oral and parenteral dosage forms, risks of systemic toxicity dictate... Read More about Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment.